The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Public awareness in early lung cancer detection and screening
Pan-Chyr Yang, MD, PhD, National Taiwan University, Taipei, Taiwan, emphasizes the importance of public awareness in lung cancer detection during. He highlights that lung cancer often presents no symptoms until advanced stages, making it crucial to identify and screen high-risk individuals early. Current data show a higher screening uptake among females with a family history of lung cancer compared to males. Prof. Yang stresses the need to use public media to educate the high-risk population about the importance of screening and who should undergo it. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Merck; Novartis; Ono Pharmaceutical
Speakers’ Bureau – AstraZeneca; Merck; Novartis; Ono Pharmaceutical; Roche
